Researchers have presented early results for a new gene therapy called PST-611, which aims to treat a common eye condition known as dry age-related macular degeneration (AMD). The Phase 1 trial involved six participants in France and focused on assessing the safety of the therapy. The results showed that PST-611 was well-tolerated, with mostly mild side effects and no serious complications. Some participants even reported improvements in their vision, which is promising for those affected by this condition.

This discovery is particularly relevant for older adults who are concerned about maintaining their vision as they age. Dry AMD is a leading cause of vision loss in people over 50, and effective treatments could help many individuals preserve their sight and overall quality of life. The early signs of potential benefits, such as improved vision and reduced lesion growth, suggest that this therapy could be a significant step forward in managing AMD.

The research is still in its early stages, with the Phase 1 trial primarily focused on safety rather than efficacy. While the results are encouraging, they do not yet confirm that PST-611 will effectively improve vision for a larger population. A Phase 2 trial is planned, which will involve more participants and assess the therapy’s effectiveness over a longer period. This next phase is expected to begin in late 2026, with results anticipated by 2028.

As this research progresses, it’s important to stay informed about new treatments for AMD. If you or someone you know is at risk for this condition, consider discussing the latest developments with a healthcare provider to explore potential options and preventive measures.

Source: longevity.technology